Jilin Aodong Pharmaceutical Group Co., Ltd. (SHE:000623)
18.54
+0.75 (4.22%)
Apr 28, 2026, 3:04 PM CST
SHE:000623 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 1,163 | 1,107 | 1,720 | 1,438 | 1,743 |
Short-Term Investments | - | - | - | 788 | 704 |
Trading Asset Securities | 1,800 | 1,568 | 1,658 | 1,640 | 2,189 |
Cash & Short-Term Investments | 2,963 | 2,675 | 3,378 | 3,866 | 4,635 |
Cash Growth | 10.76% | -20.81% | -12.62% | -16.59% | 2.71% |
Accounts Receivable | 1,001 | 1,157 | 1,407 | 1,056 | 964.31 |
Other Receivables | 25.25 | 23.18 | 29.98 | 60.31 | 68.53 |
Receivables | 1,027 | 1,181 | 1,437 | 1,116 | 1,033 |
Inventory | 802.1 | 936.9 | 872.35 | 874.57 | 591.88 |
Prepaid Expenses | - | - | - | - | 0.16 |
Other Current Assets | 31.38 | 40.41 | 57.55 | 124.69 | 65.59 |
Total Current Assets | 4,823 | 4,833 | 5,745 | 5,982 | 6,326 |
Property, Plant & Equipment | 2,356 | 2,558 | 2,534 | 2,339 | 2,296 |
Long-Term Investments | 26,473 | 24,647 | 23,003 | 21,891 | 19,637 |
Other Intangible Assets | 404.52 | 437.32 | 435.35 | 365.08 | 359.61 |
Long-Term Deferred Tax Assets | 269.99 | 326.23 | 309.84 | 303.12 | 164.27 |
Long-Term Deferred Charges | 37.63 | 111.57 | 163.96 | 212.25 | 188.02 |
Other Long-Term Assets | 54.04 | 88.33 | 75.77 | 89.83 | 96.53 |
Total Assets | 34,418 | 33,002 | 32,266 | 31,182 | 29,067 |
Accounts Payable | 310.42 | 425.71 | 418.59 | 450.97 | 238.22 |
Accrued Expenses | 113.71 | 106.87 | 148.94 | 183.15 | 111.71 |
Short-Term Debt | 903.02 | 1,255 | 678.31 | 651.27 | 355.52 |
Current Portion of Long-Term Debt | 24.07 | - | 2,315 | - | - |
Current Portion of Leases | 9.29 | 22.48 | 17.88 | 18.23 | 25.41 |
Current Income Taxes Payable | 3.59 | 5.9 | 28.28 | 11.52 | 19.31 |
Current Unearned Revenue | 31.68 | 36.25 | 26.26 | 82.25 | 18.36 |
Other Current Liabilities | 618.28 | 611.75 | 834.8 | 817.97 | 687.19 |
Total Current Liabilities | 2,014 | 2,464 | 4,468 | 2,215 | 1,456 |
Long-Term Debt | 1,299 | 995.22 | - | 2,303 | 2,211 |
Long-Term Leases | 3.18 | 16.51 | 21.49 | 17.55 | 23.38 |
Long-Term Unearned Revenue | 212.98 | 223.87 | 247.38 | 281.6 | 313.86 |
Long-Term Deferred Tax Liabilities | 1.36 | 20.17 | 30.03 | 26.06 | 24.21 |
Total Liabilities | 3,531 | 3,720 | 4,767 | 4,844 | 4,029 |
Common Stock | 1,196 | 1,196 | 1,168 | 1,163 | 1,163 |
Additional Paid-In Capital | 4,898 | 4,852 | 4,035 | 3,947 | 3,980 |
Retained Earnings | 24,275 | 22,466 | 21,871 | 20,741 | 19,243 |
Treasury Stock | -420.01 | -300 | -720.07 | -570.07 | -400.03 |
Comprehensive Income & Other | 717.38 | 814.1 | 856.99 | 753.71 | 873.11 |
Total Common Equity | 30,667 | 29,028 | 27,212 | 26,034 | 24,859 |
Minority Interest | 220.23 | 254.65 | 288.01 | 303.54 | 179.26 |
Shareholders' Equity | 30,887 | 29,282 | 27,500 | 26,338 | 25,039 |
Total Liabilities & Equity | 34,418 | 33,002 | 32,266 | 31,182 | 29,067 |
Total Debt | 2,239 | 2,289 | 3,032 | 2,990 | 2,616 |
Net Cash (Debt) | 724 | 385.96 | 346.02 | 875.84 | 2,020 |
Net Cash Growth | 87.58% | 11.54% | -60.49% | -56.63% | -0.57% |
Net Cash Per Share | 0.62 | 0.33 | 0.27 | 0.67 | 1.60 |
Filing Date Shares Outstanding | 1,172 | 1,172 | 1,123 | 1,127 | 1,139 |
Total Common Shares Outstanding | 1,172 | 1,180 | 1,123 | 1,127 | 1,139 |
Working Capital | 2,809 | 2,369 | 1,277 | 3,767 | 4,870 |
Book Value Per Share | 26.16 | 24.61 | 24.23 | 23.10 | 21.83 |
Tangible Book Value | 30,262 | 28,590 | 26,776 | 25,669 | 24,500 |
Tangible Book Value Per Share | 25.81 | 24.24 | 23.84 | 22.78 | 21.51 |
Buildings | 2,290 | 2,287 | 2,202 | 2,138 | 2,039 |
Machinery | 1,534 | 1,512 | 1,491 | 1,413 | 1,321 |
Construction In Progress | 324.63 | 424.87 | 349.54 | 177.36 | 179.32 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.